What is Eccogene?
Eccogene is dedicated to pioneering best-in-class small molecule therapeutics designed to combat chronic cardiometabolic and inflammatory diseases. The company's strategic focus is on creating oral therapies that offer improved safety profiles and efficacy, potentially augmenting the benefits of GLP-1 receptor agonists beyond weight management. Eccogene's pipeline features promising clinical programs targeting THR-β and SSAO, alongside preclinical initiatives for various metabolic disorders. The company's overarching mission is to enhance patient care and broaden access to affordable medicines for individuals worldwide affected by these prevalent conditions.
How much funding has Eccogene raised?
Eccogene has raised a total of $25M across 1 funding round:
Series B
$25M
Series B (2023): $25M with participation from Zhangjiang Healthcare Venture Capital, Huajin Capital, Oriza Seed Capital, and New Alliance Capital
Key Investors in Eccogene
Zhangjiang Healthcare Venture Capital
Zhangjiang Healthcare Venture Capital is an investor participating in the funding round.
Huajin Capital
Huajin Capital is an investor participating in the funding round.
New Alliance Capital
New Alliance Capital is a venture capital firm based in Shanghai, China, likely focusing on investments within the healthcare and technology sectors.
What's next for Eccogene?
With this major enterprise-level funding, Eccogene is poised for significant advancement in its clinical development pipeline. The strategic investment will likely accelerate the progression of its THR-β and SSAO programs through clinical trials, aiming to validate their therapeutic potential. Furthermore, the backing will support the expansion of its preclinical research into new metabolic disease targets. This capital injection signals confidence in Eccogene's strategy to address unmet medical needs and potentially redefine treatment paradigms for cardiometabolic and inflammatory diseases, positioning the company for future growth and market impact.
See full Eccogene company page
